Prostate Cancer & PSA Tumors News Articles

Prostate Cancer News

PROSTATE CANCER ADVISOR

Prostate Cancer News

Bone Metastases

Optimal Drug Sequencing for mCRPC Reported

For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.
The author positioned for radiation treatment under a linear accelerator.

Prostate Cancer Salvage Combo Benefits Confirmed

A post-hoc analysis of a phase 3 trial demonstrated that adding 6 months of androgen deprivation therapy to salvage radiotherapy for recurrent prostate cancer following radical prostatectomy improves progression-free survival at 120 months.
PET scan PCa metastases

PARP-Inhibiting Drug May Improve mCRPC Outcomes

In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.